Norris alderson fda biography
- Work Biography for Norris Alderson, U.S. Food & Drug Administration.
- And Norris Alderson is the one who came in and called me and asked me to fill that role.
- Maria Allende.
- •
Medical Device Daily Washington Editor
WASHINGTON – The development and use of nanoscale materials is hardly new, and nanoscience promises to play a much larger role in devices and drugs in the decades to come. Hence, the Food and Drug Law Institute (FDLI; Washington) last week sponsored its first of what is planned to be an annual symposium on nanotechnology.
While attendees may have expected to hear about different FDA approaches to device and drug applications that incorporate nanomaterials, the consensus among panelists from the agency and the private sector was that the agency has the expertise it needs to review nano-products and requires no new regulatory apparatus to ensure nanotech product safety.
Additionally, the phrase “case-by-case basis” was employed routinely when specific regulatory questions were posed.
Ralph Hall, PhD, of the law firm of Baker and Daniels (Minneapolis), said “one of the key regulatory issues is whether nanotechnology is just another new technology.” Assuming it is new, he said, “the core issue
- •
The Bush administration's love affair with animals
We're not saying there's a connection here, but we're not saying there isn't, either.
Remember how George W. Bush selected as his FEMA director a man whose last job involved judging horse shows for the International Arabian Horse Association? Well, the president's Food and Drug Administration commissioner has appointed an acting director for the Office of Women's Health, and he's a man -- a man! -- who has spent much of his career working in the field of veterinary medicine.
The FDA had an opening to fill in the Office of Women's Health because its last director, Susan Wood, quit in protest over the agency's dithering and delays on the morning-after pill. Wood's acting replacement is Norris Alderson. Alderson has a bachelor's degree in animal husbandry from the University of Tennessee and graduate degrees from the University of Kentucky. He has worked at the FDA for more than 30 years, more than 20 of which he spent in the agency's Bureau of Veterinary Medicine.
Karen Pearl, the interim president of Planned Parenthood, sai
- •
Moving forward responsibly: Oversight for the nanotechnology-biology interface
Abstract
Challenges and opportunities for appropriate oversight of nanotechnology applied to or derived from biological systems (nano-bio interface) were discussed in a public workshop and dialog hosted by the Center for Science, Technology, and Public Policy of the University of Minnesota on September 15, 2005. This paper discusses the themes that emerged from the workshop, including the importance of analyzing potential gaps in current regulatory systems; deciding upon the general approach taken toward regulation; employing non-regulatory mechanisms for governance; making risk and other studies transparent and available to the public; bolstering mechanisms for public participation in risk analysis; creating more opportunities for meaningful discussion of the social and ethical dimensions of the nano-bio interface; increasing funds for implications and problem-solving research in this area; and having independent and reliable sources for communication. The workshop was successful in identifying way
Copyright ©armywing.pages.dev 2025